BR112023025188A2 - METHODS OF USING ANTI-SORTILIN ANTIBODIES - Google Patents

METHODS OF USING ANTI-SORTILIN ANTIBODIES

Info

Publication number
BR112023025188A2
BR112023025188A2 BR112023025188A BR112023025188A BR112023025188A2 BR 112023025188 A2 BR112023025188 A2 BR 112023025188A2 BR 112023025188 A BR112023025188 A BR 112023025188A BR 112023025188 A BR112023025188 A BR 112023025188A BR 112023025188 A2 BR112023025188 A2 BR 112023025188A2
Authority
BR
Brazil
Prior art keywords
sortilin
methods
antibodies
sortilin antibodies
matured
Prior art date
Application number
BR112023025188A
Other languages
Portuguese (pt)
Inventor
C Mangal Brian
Leejia Yeh Felix
Y Huang Julie
F Ward Michael
Rizwan Siddiqui Omer
Robert Paul
Sam Jackson
Whedy Wang
Yijie Liao
Original Assignee
Alector Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alector Llc filed Critical Alector Llc
Publication of BR112023025188A2 publication Critical patent/BR112023025188A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

métodos de uso de anticorpos anti-sortilina. a presente invenção é, de modo geral, direcionada ao uso de composições que incluem anticorpos, por exemplo, anticorpos monoclonais, quiméricos, amadurecidos por afinidade ou humanizados, fragmentos de anticorpos, etc., que se ligam especificamente a um ou mais epítopos dentro de uma proteína sortilina, por exemplo, sortilina humana ou sortilina de mamífero, e têm características funcionais melhoradas e/ou realçadas, no tratamento e/ou retardar a progressão de uma doença ou lesão em um indivíduo em necessidade dos mesmos.methods of using anti-sortilin antibodies. The present invention is generally directed to the use of compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, or humanized antibodies, antibody fragments, etc., that specifically bind to one or more epitopes within a sortilin protein, e.g., human sortilin or mammalian sortilin, and have improved and/or enhanced functional characteristics, in treating and/or slowing the progression of a disease or injury in an individual in need thereof.

BR112023025188A 2021-06-08 2022-06-08 METHODS OF USING ANTI-SORTILIN ANTIBODIES BR112023025188A2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163208238P 2021-06-08 2021-06-08
US202163209360P 2021-06-10 2021-06-10
US202163225916P 2021-07-26 2021-07-26
US202163277069P 2021-11-08 2021-11-08
US202263304522P 2022-01-28 2022-01-28
US202263311379P 2022-02-17 2022-02-17
PCT/US2022/072827 WO2022261648A2 (en) 2021-06-08 2022-06-08 Methods of use of anti-sortilin antibodies

Publications (1)

Publication Number Publication Date
BR112023025188A2 true BR112023025188A2 (en) 2024-02-27

Family

ID=84426402

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023025188A BR112023025188A2 (en) 2021-06-08 2022-06-08 METHODS OF USING ANTI-SORTILIN ANTIBODIES

Country Status (5)

Country Link
US (1) US20240132597A1 (en)
EP (1) EP4351728A2 (en)
BR (1) BR112023025188A2 (en)
CA (1) CA3220428A1 (en)
WO (1) WO2022261648A2 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202006677XA (en) * 2018-01-25 2020-08-28 Biogen Ma Inc Methods of treating spinal muscular atrophy
TW202112817A (en) * 2019-06-11 2021-04-01 美商阿列克特有限責任公司 Methods of use of anti-sortilin antibodies

Also Published As

Publication number Publication date
US20240132597A1 (en) 2024-04-25
WO2022261648A2 (en) 2022-12-15
CA3220428A1 (en) 2022-12-15
EP4351728A2 (en) 2024-04-17
WO2022261648A3 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
CL2021003327A1 (en) Anti-sortilin antibodies and methods for their use. (request division 202100089).
BR112021025077A2 (en) Anti-sortilin antibodies for use in therapy
BR112022019892A2 (en) METHODS FOR TREATMENT AND/OR DELAYING THE PROGRESSION OF A DISEASE OR INJURY AND FOR MONITORING THE TREATMENT OF AN INDIVIDUAL
ZA202211057B (en) Anti-trem2 antibodies and methods of use thereof
EA201792221A1 (en) ANTIBODIES AGAINST SORTILINE AND METHODS OF THEIR APPLICATION
EA201791127A1 (en) ANTIBODIES CONTAINING MODIFIED CONSTANT SITES OF HEAVY CHAINS
WO2017075432A3 (en) Anti-siglec-9 antibodies and methods of use thereof
WO2017152102A3 (en) Anti-trem1 antibodies and methods of use thereof
PH12019502463A1 (en) Anti-cd33 antibodies and methods of use thereof
BR112018074847A2 (en) anti hla-g specific antibodies
BRPI0821658B8 (en) human monoclonal antibody or an antigen-binding fragment thereof that binds to hnkg2d and its uses
BR112022011570A2 (en) ANTI-MERTK ANTIBODIES AND METHODS OF THEIR USE
EA202190138A1 (en) ANTI-SIRP-BETA1 ANTIBODIES AND METHODS OF THEIR USE
BR112022001733A2 (en) ANTI-MS4A4A ANTIBODIES AND METHODS OF USE THEREOF
MX2021000933A (en) Anti-siglec-5 antibodies and methods of use thereof.
MX2022004058A (en) Kir3dl3 is an inhibitory receptor of the immune system and uses thereof.
EA202092595A1 (en) ANTIBODIES TO SIGLEC-7 AND METHODS OF THEIR APPLICATION
BR112023025188A2 (en) METHODS OF USING ANTI-SORTILIN ANTIBODIES
BR112022011337A2 (en) METHOD TO TREAT AND/OR DELAY THE PROGRESSION OF A DISEASE OR INJURY IN AN INDIVIDUAL
CL2022003296A1 (en) Anti-cd200r1 antibodies and methods of using the same
AR122237A1 (en) ANTI-SORTILINA ANTIBODIES AND METHODS FOR THEIR USE
EA201992335A1 (en) ANTIBODIES AGAINST SORTILIN AND WAYS OF THEIR APPLICATION
EA201992319A1 (en) ANTI-CD33 ANTIBODIES AND WAYS OF THEIR APPLICATION
EA201992324A1 (en) ANTI-TREM2 ANTIBODIES AND WAYS OF THEIR APPLICATION
EA202092497A1 (en) ANTI-CD27 AND ANTI-PD-L1 ANTI-BODIES AND BISPECIFIC CONSTRUCTIONS